Term
Irritable Bowel Syndrome What is it?: What are the types?: |
|
Definition
What is it?:A GI Motility Disorder -characterized by: Abdominal Cramps, difficulty defactiing, bloating, diarrhea, constipation *The CNS maybe involved that affects GI motility What are the types?: -Diarrhea-predominant -constipation-predominant -mixed constipation and diarrhea |
|
|
Term
|
Definition
• Goal is to reduce frequency and severity of symptoms • Anti-spasmodic/anti-cholinergic drugs • Anti-depressants (TCAs or SSRIs) • laxatives for constipation-predominant form • anti-diarrheals for diarrhea-predominant form – Imodium, Lomotil |
|
|
Term
Anti-spasmodic/anti-cholinergic drugs for IBS |
|
Definition
| – relax GI smooth muscle, reduce gut motility – antimuscarinic drugs (dicyclomine) for chronic use – sublingual hyoscyamine used in an acute attack |
|
|
Term
| Anti-depressants (TCAs or SSRIs) |
|
Definition
| – TCAs slow intestinal transit, used for IBS-D – SSRIs increase bowel movements, used for IBS-C – reduce abdominal pain – low dose; effects within a week |
|
|
Term
|
Definition
| • Approved only for women with constipationpredominant form • partial agonist at serotonin 5-HT4 receptor in gut – serotonin increases GI motility, secretions and sensations • removed from market March 2007 – analysis of past trials showed increased risk of stroke, chest pain and MI – possible mechanisms: • 5-HT2A receptors on platelets => platelet aggregation • serotonin causes vasoconstriction in coronary vessels |
|
|
Term
|
Definition
| • Approved only for women with diarrhea-predominant form of IBS • antagonist at serotonin 5-HT3 receptor in gut – decreases intestinal secretions and gut motility • Was removed from market in 2000 due to high incidence of ischemic colitis, some fatal • Reintroduced in 2002 via a limited distribution system |
|
|
Term
|
Definition
|
|
